VANCOUVER, British Columbia, April 02, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, ...
Toronto, Ontario--(Newsfile Corp. - June 7, 2024) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland"), a company engaged in the production, growth, and sale of ...
Relmada Therapeutics’ attempts to see whether a magic mushroom extract could be used to treat obesity and metabolic diseases may be coming to an end before they really began. The biotech launched a ...
Psilocybin is known as the active compound in so-called “magic mushrooms”, yet most psilocybin used in clinical trials today is synthesized in laboratories without the use of biological material. As ...
The DEA has forwarded a petition to change the federal regulatory classification for psilocybin, the psychedelic compound found in "magic mushrooms," to HHS for a medical and scientific review. The ...
The approval to initiate this Phase 2 clinical trial represents a pivotal moment in the clinical development of Optimi's GMP natural psilocybin extract capsules. Building on its established status as ...
Canada has licensed a startup to export psychedelics to Australia for patient use, the latest milestone in a contest to supply the potential growth of medical psychedelic drugs. Canada’s health ...
In a review of previous studies, McMaster University researchers observe a stronger signal for psilocybin as a treatment for obsessive-compulsive disorder than cannabinoids. Obsessive-compulsive ...
Colorado could limit the state’s emerging magic mushroom industry to one strain and severely restrict the use of psilocybin extractions, according to the final draft of proposed natural medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results